Publications
  1. Adoke Yeka, Jane Achan , Umberto DeAllesandro, Ambrose Talisuna. “Quinine monotherapy for treatment of recurrent uncomplicated malaria in the era of ACT’s: an appropriate public health policy? The Lancet Infectious Diseases,  Volume 9, Issue 7, Pages 448 - 452, July 2009.

  2. Adoke Yeka, Grant Dorsey, Moses R. Kamya, Ambrose Talisuna, Myers Lugemwa, John Bosco Rwakimari, Sarah G. Staedke, Philip J. Rosenthal, Fred Wabwire-Mangen, Hasifa Bukirwa. “Artemether-Lumefantrine Versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Falciparum Malaria: A Randomized Trial to Guide National Policy in Uganda” PLoS ONE, 2008, Volume 3, Issue 6, e2390

  3. Sarah G. Staedke, Prasanna Jagannathan, Adoke Yeka, Hasifa Bukirwa, Kristin Banek, Catherine Maiteki-Sebuguzi, Tamara D. Clark, Bridget Nzarubara, Denise Njama-Meya, Heidi Hopkins, Philip J. Rosenthal, Moses R. Kamya, Fred Wabwire-Mangen, Grant Dorsey, Ambrose O. Talisuna “Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda” Malaria Journal 2008, 7:107

  4. Moses R. Kamya, Adoke Yeka, Hasifa Bukirwa, Myers Lugemwa, John B. Rwakimari, Sarah G. Staedke, Ambrose O. Talisuna, Bryan Greenhouse, Francois Nosten, Philip J. Rosenthal, Fred Wabwire-Mangen, Grant Dorsey: Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial, PLoS Clinical Tials May 2007 e20

  5. Hasifa B, Adoke Y, Moses RK, Ambrose T, Kristin B, Nathan B, John BR, Philip JR, Fred WM, Grant D, Sarah GS. “Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda” PLOS Clinical Trials. 2006 May e7.

  6. Kamya MR, Gasasira AF, Yeka A, Bakyaita N, Nsobya SL, Francis D, Rosenthal PJ, Dorsey G, Havlir D.  “Effect of HIV infection on malaria treatment outcomes in Uganda; A population based study.” JID 2006:193:9-15

  7. Lee SA, Yeka A, Nsobya SL, Dokomajilar C, Rosenthal PJ, Talisuna A, Dorsey G.  “Complexity of Plasmodium falciparum infections and antimalarial drug efficacy at seven sites in Uganda.” J Infect Dis. 2006 Apr 15;193(8):1160-3

  8. Francis D, Nsobya SL, Talisuna A, Yeka A, Kamya MR, Machekano R, Dokomajilar C, Rosenthal PJ, Dorsey G.  “Geographic differences in antimalarial drug efficacy explained by differences in endemicity and not molecular markers of drug resistance.” J Infect Dis. 2006 Apr 1;193(7):978-86.

  9. Myrick A, Leemann E, Dokomajilar C, Hopkins H, Dorsey G, Kamya M, Rosenthal PJ.  “The dynamics of falciparum malaria after sub-optimal therapy in Uganda.”  (submitted)

  10. Eggena M, Hopkins H, Barugahare B, Okello M, Ssali F, Mugyenyi P, Rosenthal PJ, Cao H, Dorsey G.  “CD4 T cell activation is a predictor for treatment failure in Ugandans with falciparum malaria.”  Am J Trop Med Hyg. (in press)

  11. Yeka A, Banek K, Bakyaita N, Staedke SG, Kamya MR, Talisuna A, Kironde F, Nsobya SL, Kilian A, Slater M, Reingold A, Rosenthal PJ, Wabwire-Mangen F, Dorsey G. “Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda.”  PLoS Med. 2005 Jul;2(7):e190.

  12. Bakyaita N, Dorsey G, Yeka A, Banek K, Staedke SG, Kamya MR, Talisuna A, Kironde F, Nsobya S, Kilian A, Reingold A, Rosenthal PJ, Wabwire-Mangen F.  “Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda.”  Am J Trop Med Hyg. 2005 May;72(5):573-80.

  13. Dorsey G, Dokomajilar C, Kiggundu M, Staedke SG, Kamya MR, Rosenthal PJ.  “Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda.”  Am J Trop Med Hyg. 2004 Dec;71(6):758-63.

  14. Parikh S, Dorsey G, Rosenthal PJ.  “Host polymorphisms and the incidence of malaria in Ugandan children.”  Am J Trop Med Hyg. 2004 Dec;71(6):750-3.

  15. Dorsey G, Gasasira AF, Machekano R, Kamya MR, Staedke SG, Hubbard A.  “The impact of age, temperature, and parasite density on treatment outcomes from antimalarial clinical trials in Kampala, Uganda.”  Am J Trop Med Hyg. 2004 Nov;71(5):531-6.

  16. Staedke SG, Mpimbaza A, Kamya MR, Nzarubara BK, Dorsey G, Rosenthal PJ.  “Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial.” Lancet. 2004 Nov 27-Dec 3;364(9449):1950-7.”

  17. Njama-Meya D, Kamya MR, Dorsey G.  “Asymptomatic parasitaemia as a risk factor for symptomatic malaria in a cohort of Ugandan children.”  Trop Med Int Health. 2004 Aug;9(8):862-8.

  18. Nsobya SL, Parikh S, Kironde F, Lubega G, Kamya MR, Rosenthal PJ, Dorsey G.  “Molecular evaluation of the natural history of asymptomatic parasitemia in Ugandan children.”  J Infect Dis. 2004 Jun 15;189(12):2220-6.

  19. Staedke SG, Sendagire H, Lamola S, Kamya MR, Dorsey G, Rosenthal PJ.  “Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda.”  Trop Med Int Health. 2004 May;9(5):624-9.

  20. Kyabayinze D, Cattamanchi A, Kamya MR, Rosenthal PJ, Dorsey G.  “Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria.”  Am J Trop Med Hyg. 2003 Sep;69(3):247-52.

  21. Staedke SG, Nottingham EW, Cox J, Kamya MR, Rosenthal PJ, Dorsey G.  “Short report: proximity to mosquito breeding sites as a risk factor for clinical malaria episodes in an urban cohort of Ugandan children.”  Am J Trop Med Hyg. 2003 Sep;69(3):244-6.

  22. Dorsey G, Vlahos J, Kamya MR, Staedke SG, Rosenthal PJ.  “Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria.”  J Infect Dis. 2003 Oct 15;188(8):1231-8.

  23. Njama D, Dorsey G, Guwatudde D, Kigonya K, Greenhouse B, Musisi S, Kamya MR.  “Urban malaria: primary caregivers' knowledge, attitudes, practices and predictors of malaria incidence in a cohort of Ugandan children.”  Trop Med Int Health. 2003 Aug;8(8):685-92.

  24. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G.  “Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp.”  Am J Trop Med Hyg. 2003 Feb;68(2):133-9.

  25. Gasasira AF, Dorsey G, Nzarubara B, Staedke SG, Nassali A, Rosenthal PJ, Kamya MR.  “Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda.”  Am J Trop Med Hyg. 2003 Feb;68(2):127-32.

  26. Dorsey G, Njama D, Kamya MR, Cattamanchi A, Kyabayinze D, Staedke SG, Gasasira A, Rosenthal PJ.  “Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial.”  Lancet. 2002 Dec 21-28;360(9350):2031-8.

  27. Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED, Rosenthal PJ. “Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial.”  Lancet. 2001 Aug 4;358(9279):368-74.

  28. Dorsey G, Kamya MR, Ndeezi G, Babirye JN, Phares CR, Olson JE, Katabira ET, Rosenthal PJ..  “Predictors of chloroquine treatment failure in children and adults with falciparum malaria in Kampala, Uganda.”  Am J Trop Med Hyg. 2000 Jun;62(6):686-92.

  29. Dorsey G, Kamya MR, Singh A, Rosenthal PJ.  “Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda.”  J Infect Dis. 2001 May 1;183(9):1417-20.

  30. Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Babirye JN, Staedke SG, Rosenthal PJ.  “The comparative efficacy of chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Kampala, Uganda.”  Trans R Soc Trop Med Hyg. 2001 Jan-Feb;95(1):50-5.